---
title: "Incyte Corporation (INCY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/INCY.US.md"
symbol: "INCY.US"
name: "Incyte Corporation"
industry: "Biotechnology"
datetime: "2026-05-20T05:55:05.706Z"
locales:
  - [en](https://longbridge.com/en/quote/INCY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/INCY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/INCY.US.md)
---

# Incyte Corporation (INCY.US)

## Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF;  INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.incyte.com](https://www.incyte.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: B (0.21)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 14 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.48% |  |
| Net Profit YoY | 6631.44% |  |
| P/B Ratio | 3.37 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 18944188922.34 |  |
| Revenue | 5361020000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 30.82% | A |
| Profit Margin | 26.71% | A |
| Gross Margin | 51.25% | B |
| Revenue YoY | 21.48% | B |
| Net Profit YoY | 6631.44% | A |
| Total Assets YoY | 27.65% | A |
| Net Assets YoY | 53.31% | A |
| Cash Flow Margin | 105.94% | C |
| OCF YoY | 21.48% | B |
| Turnover | 0.82 | B |
| Gearing Ratio | 23.39% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Incyte Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21.48%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "6631.44%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.37",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "18944188922.34",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5361020000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "30.82%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "26.71%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "51.25%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "21.48%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "6631.44%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "27.65%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "53.31%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "105.94%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "21.48%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.82",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "23.39%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 13.29 | 27/386 | 20.03 | 17.41 | 15.05 |
| PB | 3.38 | 273/386 | 4.26 | 3.89 | 3.60 |
| PS (TTM) | 3.55 | 83/386 | 4.11 | 3.68 | 3.27 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **26**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 35% |
| Overweight | 2 | 8% |
| Hold | 13 | 50% |
| Underweight | 1 | 4% |
| Sell | 1 | 4% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 95.60 |
| Highest Target | 135.00 |
| Lowest Target | 71.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/INCY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/INCY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/INCY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/INCY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**